BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 12690090)

  • 1. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
    Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
    Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study.
    Duvillard L; Pont F; Florentin E; Galland-Jos C; Gambert P; Vergès B
    Eur J Clin Invest; 2000 Aug; 30(8):685-94. PubMed ID: 10964160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men.
    Chan DC; Watts GF; Ng TW; Uchida Y; Sakai N; Yamashita S; Barrett PH
    Clin Biochem; 2005 Sep; 38(9):806-12. PubMed ID: 15992790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.
    Watts GF; Ji J; Chan DC; Ooi EM; Johnson AG; Rye KA; Barrett PH
    Clin Sci (Lond); 2006 Sep; 111(3):193-9. PubMed ID: 16700661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of obesity on the metabolism of apolipoprotein B in humans.
    Egusa G; Beltz WF; Grundy SM; Howard BV
    J Clin Invest; 1985 Aug; 76(2):596-603. PubMed ID: 4031064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
    Ikewaki K; Schaefer JR; Frischmann ME; Okubo K; Hosoya T; Mochizuki S; Dieplinger B; Trenkwalder E; Schweer H; Kronenberg F; Koenig P; Dieplinger H
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.
    Tremblay AJ; Lamarche B; Cohn JS; Hogue JC; Couture P
    Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1101-6. PubMed ID: 16528005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status.
    Matthan NR; Jalbert SM; Lamon-Fava S; Dolnikowski GG; Welty FK; Barrett HR; Schaefer EJ; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1691-6. PubMed ID: 15933247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome.
    Watts GF; Chan DC; Barrett PH; O'Neill FH; Thompson GR
    Int J Obes Relat Metab Disord; 2003 Jul; 27(7):862-5. PubMed ID: 12821974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of short- and long-term growth hormone replacement on lipoprotein composition and on very-low-density lipoprotein and low-density lipoprotein apolipoprotein B100 kinetics in growth hormone-deficient hypopituitary subjects.
    Kearney T; de Gallegos CN; Proudler A; Parker K; Anayaoku V; Bannister P; Venkatesan S; Johnston DG
    Metabolism; 2003 Jan; 52(1):50-9. PubMed ID: 12524662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome.
    Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH
    Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fat compartments and apolipoprotein B-100 kinetics in overweight-obese men.
    Watts GF; Chan DC; Barrett PH; Susekov AV; Hua J; Song S
    Obes Res; 2003 Jan; 11(1):152-9. PubMed ID: 12529498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary plant sterols supplementation does not alter lipoprotein kinetics in men with the metabolic syndrome.
    Ooi EM; Watts GF; Barrett PH; Chan DC; Clifton PM; Ji J; Nestel PJ
    Asia Pac J Clin Nutr; 2007; 16(4):624-31. PubMed ID: 18042521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma markers of cholesterol homeostasis in metabolic syndrome subjects with or without type-2 diabetes.
    Ooi EM; Ng TW; Chan DC; Watts GF
    Diabetes Res Clin Pract; 2009 Sep; 85(3):310-6. PubMed ID: 19573945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency.
    Ikewaki K; Nishiwaki M; Sakamoto T; Ishikawa T; Fairwell T; Zech LA; Nagano M; Nakamura H; Brewer HB; Rader DJ
    J Clin Invest; 1995 Sep; 96(3):1573-81. PubMed ID: 7657828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microsomal triglyceride transfer protein -493T variant reduces IDL plus LDL apoB production and the plasma concentration of large LDL particles.
    Lundahl B; Skoglund-Andersson C; Caslake M; Bedford D; Stewart P; Hamsten A; Packard CJ; Karpe F
    Am J Physiol Endocrinol Metab; 2006 Apr; 290(4):E739-45. PubMed ID: 16291571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men.
    Chan DC; Watts GF; Wang J; Hegele RA; van Bockxmeer FM; Barrett PH
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):45-51. PubMed ID: 18031309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG
    J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.